PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer

Okuda, Yohei; Kato, Taigo; Ishizuya, Yu et al.

International Journal of Urology, 2025

Number of Access:164（2025-10-12 12:23 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/102228

Link to primary information 

File Format Terms of use Size Views Date.Available Description information
IntJofUrology pdf None 237 KB 26 2025.07.10  
Creative Commons : Attribution - NonCommercial - NoDerivatives

Item Information

Output File Export EndNote Basic Export Mendeley

Title
PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer
Creator
NRID
1000010964372 1000010964372
ORCID
0000-0001-9909-4200 0000-0001-9909-4200
researchmap permalink
okudayohei okudayohei
CreatorName
Okuda, Yohei
NRID
1000070648021 1000070648021
researchmap permalink
taigokato taigokato
Scopus Author ID
55414697500 55414697500
ORCID
0000-0002-8681-1407 0000-0002-8681-1407
CreatorName
Kato, Taigo
NRID
1000000783854 1000000783854
researchmap permalink
okiishi okiishi
CreatorName
Ishizuya, Yu
NRID
1000050747079 1000050747079
researchmap permalink
takuhaya takuhaya
CreatorName
Hayashi, Takuji
NRID
1000090759557 1000090759557
researchmap permalink
yoshi229 yoshi229
ORCID
0000-0002-1271-3521 0000-0002-1271-3521
CreatorName
Yamamoto, Yoshiyuki
NRID
1000060762234 1000060762234
researchmap permalink
koji_hatano koji_hatano
Scopus Author ID
14627167600 14627167600
CreatorName
Hatano, Koji
NRID
1000050746568 1000050746568
researchmap permalink
akawashima akawashima
Scopus Author ID
9846139400 9846139400
CreatorName
Kawashima, Atsunari
NRID
1000060532603 1000060532603
CreatorName
Murai, Junko
NRID
1000030263263 1000030263263
researchmap permalink
read0185096 read0185096
Scopus Author ID
7005880662 7005880662
CreatorName
Nonomura, Norio
Description
Okuda Yohei, Kato Taigo, Ishizuya Yu, et al. PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer. International Journal of Urology (2025); https://doi.org/10.1111/iju.70100.
Abstract
Alterations in the homologous recombination repair genes, such as BRCA1 and BRCA2, are prevalent in various cancers, presenting a unique opportunity to develop synthetic lethal strategies that target homologous recombination deficiency (HRD). Poly ADP-ribose polymerase inhibitors (PARPis) have been developed to induce synthetic lethality in tumors with HRD by inhibiting the repair of single-strand DNA breaks. Beyond the initial approach to target cancers associated with HRD, the utility of PARPis has expanded to combination therapy with immune checkpoint inhibitors, anti-angiogenic drugs, or anti-androgen drugs based on the molecular biological rationale. In the field of genitourinary (GU) cancer, PARPis, such as olaparib, rucaparib, and talazoparib, are approved by the Food and Drug Administration in metastatic prostate cancer patients with BRCA1/2 mutations, sometimes in combination with other agents (e.g., olaparib plus abiraterone acetate, or talazoparib plus enzalutamide). More recently, pivotal clinical trials have broadened the potential of PARPis to the other GU cancers, including urothelial carcinoma and renal cell carcinoma. In this review, we examine the biomarkers for the response to PARPis beyond mutations in BRCA1/2 and discuss the current state and future perspectives of PARPis in GU cancers.
Publisher
Wiley
Source Title
International Journal of Urology
Date of Issued
2025-06-09
Language
English
Handle URL
https://hdl.handle.net/11094/102228
PISSN
09198172
eISSN
14422042
Relation.isIdenticalTo
DOI (Publisher Version)
https://doi.org/10.1111/iju.70100
Access Rights
open access
CopyRight
© 2025 The Author(s). International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association.
This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
oaire:version
Version of Record
Category
学術雑誌論文 Journal Article